Indications for Galvus®
Type 2 diabetes mellitus (in combination with diet therapy and exercise):
as monotherapy in case of ineffectiveness of diet therapy and exercise in patients with contraindication to the use/intolerance to metformin or in case of ineffectiveness of metformin;
in combination with metformin as initial drug therapy in case of insufficient effectiveness of diet therapy and exercise;
as part of a two-component combination therapy: with metformin or thiazolidinedione, or with insulin in case of ineffectiveness of diet therapy, exercise and monotherapy with these drugs;
as part of a two-component combination therapy with sulfonylurea derivatives in patients with insufficient glycemic control against the background of the maximum tolerated dose of a sulfonylurea derivative or in the presence of contraindications to the use/intolerance to metformin;
as part of triple combination therapy: in combination with sulfonylurea derivatives and metformin, in patients previously treated with sulfonylurea derivatives and metformin with diet and exercise therapy and who have not achieved adequate glycemic control;
as part of triple combination therapy: in combination with insulin and metformin, in patients previously treated with a stable dose of insulin and metformin with diet and exercise therapy and who have not achieved adequate glycemic control.
Contraindications for use
hypersensitivity to vildagliptin or any other components of the drug;
hereditary galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption;
type 1 diabetes mellitus;
acute or chronic metabolic acidosis (including diabetic ketoacidosis with or without coma). Diabetic ketoacidosis should be corrected with insulin therapy. Lactic acidosis (including history);
liver dysfunction, including patients with increased activity of “liver” enzymes (ALT or AST 3 or more times higher than ULN /3×ULN/);
chronic heart failure (CHF) IV FC according to the functional classification of the New York Heart Association (NYHA) (due to the lack of clinical trial data on the use of vildagliptin in this group of patients);
children under 18 years of age (the efficacy and safety of the drug have not been established).
Warning: Always consult a doctor before using medications.
